Rony Lahoud
Interventional Cardiology · South Burlington, VTNPI 1659534212
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,955 of the $99,251 with a category attached, or 79.6%. 5 manufacturers reported payments, led by Medtronic at 59.9% of the total. 2025 is the largest year on record at $54,266, more than ten times the $1,423 reported in 2019.
Across 75 payments — averaging $1323.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$59K
- Abbott$32K
- Edwards Lifesciences$6K
- Boston Scientific$1K
- AstraZeneca$14
Across 70 payments — averaging $9514.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$574K
- Shockwave Medical, Inc$59K
- Abbott$34K
What the payments were for
- Consulting fees$3,3753%
- Speaking & faculty fees$78,95580%
- Travel & lodging$15,18315%
- Food & beverage$1,7382%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 31 | $59,426 |
| Abbott | 19 | $32,031 |
| Edwards Lifesciences | 20 | $6,358 |
| Boston Scientific | 4 | $1,423 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$47,522
- MitraClip$15,437
- TRICLIP$9,245
- SYMPLICITY G3$9,000
- DRAGONFLY OPSTAR$7,175
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,513
- EVOQUE$2,055
- Watchman$1,423
- NAVITOR$150
How this compares
Too few interventional cardiology providers in Vermontto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $16,671 |
| Praluent PenAlirocumab | 13 | $6,147 |
| ClopidogrelClopidogrel Bisulfate | 48 | $554 |
| Atorvastatin Calcium | 19 | $422 |
| Rosuvastatin Calcium | 13 | $352 |
| Metoprolol Succinate | 21 | $213 |
| Losartan Potassium | 16 | $152 |
| Lisinopril | 16 | $130 |
| Prednisone | 13 | $24 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in South Burlington
- Tanush GuptaBurlington$27K
- Jan DenkmannBurlington$5K
- Jesse KaneBurlington$3K
- Prospero GogoBurlington$894
- Magdalena ZeglinBurlington$343
- Kevin CareyBurlington$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.